By Henry Ehrlich
This website likes to feature new technologies for various allergic conditions, particularly to help patients comply with their asthma medication regimens. We do this because, as we were recently reminded, asthma represents a huge and still-growing threat to public health.
Today we’re doing something new—partnering with a company called Antidote to publicize a clinical trial for a combination asthma therapy for children aged 5-17. The investigational study drug (fluticasone furoate/vilanterol) is administered by an inhaler. This study will investigate whether a treatment option already approved in the U.S. for adults is safe and effective for children and teens. This a phase-3 study, which means that the study drug has been taken by other participants under the supervision of medical professionals.
Key Eligibility Criteria:
- Age: 5-17 years of age
- Have had asthma for at least 6 months
- Currently are treated with a daily and rescue inhaler
- Cannot have been hospitalized for asthma symptoms in the past 6 months
- Cannot have type 1 or type 2 diabetes
This study comes at a good time. In December, we were treated to this on FDA.gov:
FDA’s most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
Another First for this Website
We launched this website in 2010. In that time we have never taken in a penny of revenue except for sales of our book, Asthma Allergies Children: a parent’s guide and those sales have never compensated us for the cost of designing or maintaining the site, let alone the editorial time involved. If, however, anyone becomes part of this study via our website, we will get paid.